Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Eden vs GoodRx

Eden
Site position #16

Higher grade

GoodRx
Site position #133

Lower grade

The verdict

Eden takes it — 81.6/100 to 69.6/100.

Eden grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Eden advertises lower-priced compounded bundles, but its offer and linked membership and warranty terms need to be reconciled before purchase.

We may earn a commission through these links, at no extra cost to you. Commercial relationships affect placement, but never the WeighScore or our editorial findings. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueEden +5
85
80
Dose & formulationEden +16
86
70
Clinical oversightGoodRx +14
55
69
Labs & monitoringEden +41
92
51
FulfillmentEden +12
93
81
Contract termsEden +35
90
55
Eden · top barGoodRx · bottom bar

The numbers

Swipe or scroll to compare both providers.

MetricEdenGoodRx
WeighScore81.6/10069.6/100
GradeB−C
Site position#16#133
SemaglutideAdvertised $99/mo bundle; linked membership terms conflict—confirm checkoutNot disclosed
TirzepatideAdvertised $129/mo bundle; linked membership terms conflict—confirm checkout$299/mo (brand Zepbound)
CoverageAll 50 statesAll 50 states
Brand-name accessYesYes
Oral / sublingualNot confirmedNot confirmed
Eden

Site position #16 · B−

FDAWarning letter issued to Eden Health International Inc. dba Eden in June 2026. See the FDA warning-letter database.

Strengths

  • Current compounded offer includes medication and support
  • Homepage also advertises branded prescription pathways; eligibility and cost require confirmation
  • Named pharmacy operation and partner network can be investigated

What to consider

  • Linked membership terms describe a separate fee model
  • Landing-page warranty and terms use different thresholds and conditions
  • FDA warning history remains relevant; a new offer does not establish resolution
GoodRx

Site position #133 · C

Strengths

  • $149/month self-pay for brand-name Foundayo (orforglipron) — matches the lowest cash price at launch, far below typical retail
  • $299/month self-pay for Zepbound KwikPen — well under Lilly's typical cash list price
  • Honored at 70,000+ US pharmacies — the largest retail redemption network of any GLP-1 channel we cover
  • No membership fee — bring your own prescription and present the discount card at the pharmacy counter
  • Brand-name FDA-approved medication, not compounded

What to consider

  • Requires a valid prescription — GoodRx is a discount card, not a prescriber; you still need a clinician to write the script
  • Self-pay only — does not apply toward insurance benefits or deductibles
  • Headline price applies to the lowest Foundayo dose; higher doses may cost more
  • No compounded GLP-1 options — not the channel for compounded semaglutide or tirzepatide
  • Pricing can change as Lilly's manufacturer coupon program evolves

Featured provider

Eden

Eden scores 81.6/100 (B−). Eden advertises lower-priced compounded bundles, but its offer and linked membership and warranty terms need to be reconciled before purchase.

Commercial relationships affect this placement. The score comparison above is separate.

FDAWarning letter issued to Eden Health International Inc. dba Eden in June 2026. See the FDA warning-letter database.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard